From Analysis:
m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA stability and protein aggregation kinetics in substantia nigra dopaminergic neurons, and can pharmacological manipulation of m6A writers/erasers reduce Lewy body formation in PD model systems?
N6-methyladenosine (m6A) hypermethylation of SNCA mRNA in substantia nigra dopaminergic neurons stabilises the transcript, increases alpha-synuclein protein levels, and lowers the concentration threshold for protein aggregation into Lewy bodies. Pharmacological inhibition of METTL3 (the primary m6A writer) should reduce SNCA mRNA stability, lower alpha-synuclein protein levels, and decrease aggregation in PD model neurons.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["METTL3 m6A Writer Complex
Substantia Nigra Dopaminergic Neurons"]
B["N6-Methyladenosine Hypermethylation
SNCA mRNA Specific Sites"]
C["SNCA Transcript Stabilized
Reduced mRNA Turnover Rate"]
D["Alpha-Synuclein Protein Levels Rise
Above Aggregation Threshold"]
E["Lewy Body Nucleation
Lower Critical Concentration"]
F["Lewy Body Pathology Progression
Dopaminergic Neuron Loss"]
G["Parkinson Disease Neurodegeneration"]
H["METTL3 Pharmacological Inhibition
SNCA mRNA Destabilization Strategy"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
H -.->|"reduce SNCA levels"| B
style B fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Theorist position for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
Source basis: Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease (Molecular Psychiatry, 2024, DOI 10.1038/s41380-024-02574-w). The stored gap context says: Multi-omics analysis implicated m6A modification in PD risk but the causal downstream mechanism on alpha-synuclein biology was not established.
Primary hypothesis: m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics is
Skeptic critique for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: global m6A manipulation can create broad toxicity and indirect proteostasis effects.
The debate should re
Domain expert assessment for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational bio
{
"ranked_hypotheses": [
{
"title": "m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics as proximal driver in m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra",
"description": "m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics should produce a measurable proximal phenotype before late disease pathology. The decisive test is dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays.",
"target_gene": "m6A",
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for SNCA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | failed
No comments yet. Be the first to comment!